MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/2050640617695698

Медицинская библиотека · United European gastroenterology journal · 2017

Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.

Pinter Matthias, Weinmann Arndt, Wörns Marcus-Alexander, Hucke Florian, Bota Simona, Marquardt Jens U, Duda Dan G, Jain Rakesh K, Galle Peter R, Trauner Michael, Peck-Radosavljevic Markus, Sieghart Wolfgang

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Inhibition of the renin-angiotensin system (RAS) was associated with longer survival in patients with different solid malignancies.

OBJECTIVE

The objective of this study was to investigate the effect of RAS inhibitor (RASi) treatment (angiotensin-converting enzyme inhibitors or angiotensin-II-receptor blockers) on survival of patients with hepatocellular carcinoma (HCC).

METHODS

Patients diagnosed with HCC and Child-Pugh A between 1992 and 2013 who received sorafenib, experimental therapy, or best supportive care were eligible for the Vienna cohort. The Mainz cohort included patients with HCC and Child-Pugh A who received sorafenib treatment between 2007 and 2016. The association between RASi and overall survival (OS) was evaluated in univariate and multivariate analyses.

RESULTS

In the Vienna cohort, 43 of 156 patients received RASi for hypertension. RASi treatment was associated with longer OS (11.9 vs. 6.8 months (mo); p = 0.014) and remained a significant prognostic factor upon multivariate analysis (HR = 0.6; 95% CI 0.4-0.9; p = 0.011). In subgroup analysis, patients treated with sorafenib plus RASi had better median OS (19.5 mo) compared to those treated with either sorafenib (10.9 mo) or RASi (9.7 mo) alone (p = 0.043). The beneficial effect of RASi on survival was confirmed in the Mainz cohort (n = 76).

CONCLUSION

RAS inhibition is associated with longer survival in HCC patients with Child-Pugh class A.

Для цитирования: Pinter Matthias, Weinmann Arndt, Wörns Marcus-Alexander, Hucke Florian, Bota Simona, Marquardt Jens U, Duda Dan G, Jain Rakesh K, Galle Peter R, Trauner Michael, Peck-Radosavljevic Markus, Sieghart Wolfgang. Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.. United European gastroenterology journal. 2017. DOI: 10.1177/2050640617695698.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.